Governing Through the Life Sciences Capital Crunch: Board Discipline, Value Inflection, and Leadership Readiness

Registration Opening Soon!

Life sciences companies continue to operate in a constrained capital environment, requiring boards to exercise sharper oversight of cash runway, scientific de-risking, investor readiness, leadership capability, and the company’s ability to realistically reach its next value-inflection point. In this environment, the board’s role is not simply to support the next raise. It is to determine whether additional capital should be deployed at all.

This program will examine how life sciences boards should oversee capital allocation, stage-gate decision-making, management readiness, board composition, and strategic alternatives when funding is scarce, and execution risk is high. The discussion will focus on the hard questions directors must ask before more capital, time, or resources are committed:

• Can the company realistically reach its next value-inflection point with its current runway?

• Has the company run the decisive “killer experiment” needed to validate or challenge the science?

• Is the technology sufficiently de-risked for investors, strategic partners, or the next stage of development?

• Does the CEO and leadership team have the skills required for the company’s next phase?

• Is the board prepared to reassess management at critical stages, including discovery, preclinical, clinical, regulatory, commercial, capital raise, or transaction readiness?

• Does the board have the right expertise in regulatory strategy, commercial scaling, AI and data governance, manufacturing, supply chain, capital markets, and cybersecurity?

The session will be positioned as a governance program for science-driven companies operating under capital constraints. It will not be positioned as a general capital markets update or CEO roundtable. Attendees should leave with practical boardroom questions related to capital discipline, value-inflection decisions, investor readiness, CEO and management readiness, board composition, and the board’s responsibility to challenge assumptions and protect long-term value.

Primary Governance Lens

• Capital discipline and cash runway oversight

• Value-inflection and stage-gate decision-making

• Scientific de-risking and “killer experiment” discipline

• CEO and management readiness at critical growth stages

• Investor readiness and strategic alternatives

• Board composition, skills matrix, and governance maturity

• Long-term value creation under capital constraints

By the end of this program, attendees will be able to:

• Define the board’s oversight responsibilities for cash runway, capital allocation, and value-inflection decisions in a constrained funding environment.
  
  
• Apply a governance lens to management’s scientific de-risking strategy, including the evidence, milestones, and stage gates required before additional capital is committed.
  
  
• Evaluate when the board should challenge management assumptions, reassess leadership readiness, or consider changes in management at critical stages of company development.
  
  
• Identify the board-level questions that should guide oversight of investor readiness, strategic partnerships, financing alternatives, and transaction preparedness.
  
  
• Assess whether the board’s composition, committee structure, and skills matrix align with the company’s current regulatory, scientific, commercial, operational, and risk oversight needs.

Who Should Attend

This program is designed for current and aspiring directors of life sciences companies, including directors serving private, public, venture-backed, preclinical, clinical-stage, and commercial-stage organizations. It is also relevant to board chairs, committee chairs, CEOs, and senior executives who regularly engage with their boards, to investors serving on portfolio company boards, and to professional advisers supporting life sciences governance.

Why Attend

In a capital-constrained environment, boards must do more than support the next financing. They must exercise informed, independent oversight of whether the company has a credible path to its next value-inflection point, whether management is prepared for the next stage, and whether further investment of capital, time, and resources is justified.

This program will provide directors with practical governance questions and oversight frameworks to strengthen boardroom dialogue regarding:

• Board oversight of cash runway, capital discipline, and capital-allocation decisions
  Board oversight of scientific de-risking, milestone credibility, and stage-gate decision-making

• CEO and management readiness at critical stages of growth

• Board oversight of investor readiness, strategic partnerships, financing options, and alternative paths forward

• Board composition, skills alignment, and governance maturity

• The board’s responsibility to challenge assumptions, reassess risks, and protect long-term value

Attendees will leave better equipped to fulfill their fiduciary duties and strategic oversight responsibilities as scientific promise, limited capital, and execution risk intersect.